Healthtech deals decreased significantly in the pharma industry in H1 2022
Deals relating to healthtech in the pharmaceutical sector have seen a decrease of 20.7% from H1 2021 to H1 2022, an analysis of GlobalData's deals database reveals.
Deals
Healthtech deals decreased significantly in the pharma industry in H1 2022
Artificial Intelligence-related deals significantly decreased in the pharmaceutical industry in H1 2022
Deals relating to regenerative medicine decreased significantly in the pharmaceutical industry in H1 2022
Eurocine and Redbiotec partner to develop HSV-2 vaccines
Evgen Pharma and University of Michigan to study colorectal cancer asset
Coave and ABL partner to develop gene therapy manufacturing processes
Pfizer acquires biopharma firm ReViral for up to $525m
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
